62044-37-5

Basic information

• Product Name: 4-cyanophenylacetic acid chloride
• Synonyms: 4-cyanophenylacetic acid chloride
• CAS NO: 62044-37-5
• Molecular Weight: 179.606
• Mol File: 62044-37-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-cyanophenylacetic acid chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-cyanophenylacetic acid chloride(62044-37-5)
• EPA Substance Registry System: 4-cyanophenylacetic acid chloride(62044-37-5)

Safety Data

• Hazardous Substances Data: 62044-37-5(Hazardous Substances Data)

Upstream product

• 1197-55-3 4-aminophenylacetic acid 
• 5462-71-5 4-cyanophenylacetic acid 

Downstream Products

• 79149-53-4 2-(4-cyanophenyl)-N,N-diphenylacetamide 
• 1233533-73-7 4-(2-(4-methoxyphenyl)-1H-indol-3-yl)benzonitrile 
• 79149-59-0 2-(4-cyanophenyl)-N-methyl-acetamide 
• 1456613-98-1 4-((7-oxo-5-thioxo-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)methyl)benzonitrile 
• 1456614-20-2 C₁₄H₁₄N₆O₂S 
• 117753-06-7 2-(4-cyanophenyl)acetamide 
• 1072438-49-3 (1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-icosahydro-cyclopenta[a]chrysene-3a-carboxylic acid 3-[5-(4-cyano-benzyl)-[1,2,4]oxadiazol-3-yl]-benzylamide 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain

We disclose the design of a novel series of cyanoguanidines that are potent (IC50 ? 10-100 nM) and selective (≥100-fold) P2X7 receptor antagonists against the other P2 receptor subtypes such as the P2Y2, P2X4, and P2X3. We also found that these P2X7 antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 μmol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X7 receptors in neuropathic pain and therefore a potential use of P2X7 antagonists as novel therapeutic tools for the treatment of this type of pain.